Business
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for inoperable LAPC patients who have completed first-line mFOLFIRINOX, a population for whom no standard consolidation therapy exists and whose prognosis remains poor despite completing the best available systemic treatmentApproximately 30% of the estimated 140,000 Europeans diagnosed with pancreatic cancer each year present with locally advanced, inoperable, non-
About this update from Sabre Corporation
[{"type":"image","alt":"Alpha Tau Medical Ltd.","displaySize":"","headline":null,"caption":"Alpha Tau Medical Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":215,"url":"https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7VgHu6alli3.BtV2lI3Eng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMQ--/https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40","width":300,"height":215}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for inoperable LAPC patients who have completed first-line mFOLFIRINOX, a population for whom no standard consolidation therapy exists and whose prognosis remains poor despite completing the best available systemic treatment","length":357,"tagName":"p"}]},{"val":[{"type":"text","content":"Approximately 30% of the estimated 140,000 Europeans diagnosed with pancreatic cancer each year present with locally advanced, inoperable, non-metastatic disease","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"The trial is a key pillar of Alpha Tau’s global clinical expansion strategy in Europe, alongside the ongoing IMPACT multicenter pancreatic cancer trial in the United States ","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"First patient treatment at CHU Grenoble Alpes comes ahead of Digestive Disease Week (DDW) 2026 in Chicago (May 2-5), where Alpha Tau’s pancreatic cancer program will be highlighted","length":180,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":870,"olType":false},{"type":"text","content":"JERUSALEM, April 23, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the successful treatment of the first patient in ACAPELLA (Alpha DaRT for CAncer of the PancrEas in Locally advanced Adenocarcinoma), the Company’s European multicenter clinical trial evaluating Alpha DaRT combined with capecitabine for patients with inoperable locally advanced pancreatic ductal adenocarcinoma (LAPC) who have completed first-line mFOLFIRINOX chemotherapy. The procedure was performed at CHU Grenoble A...